

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

2-23-07 Date Hann Shitaku

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

André DELACOURTE Nicolas SERGEANT

Serial No.: 10/625,854

Filed: July 23, 2003

For: PREVENTION, TREATMENT AND

DIAGNOSIS OF DISEASES

ASSOCIATED WITH BETA-AMYLOID FORMATION AND/OR AGGREGATION

Group Art Unit: 1649

Examiner: Chang-Yu Wang

Atty. Dkt. No.: 11362.0039.NPUS01

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08B (formerly PTO-1449) be considered by the Examiner and made of record. Copies of the listed documents C17-C25 required by 37 C.F.R. §1.98(a)(2) are enclosed for the convenience of the Examiner.

02/27/2007 RMEBRAHT 00000092 083038 10625854

03 FC:1806

180.00 DA

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure

Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to

patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R § 1.97(c)(2), the Commissioner is authorized to charge the

fee of \$180.00 to Deposit Account No. 08-3038/11362.0039.NPUS01. No other fees are

believed to be due in connection with the filing of this Supplemental

Information Disclosure Statement, however, should any additional fees be required for any

reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees

from the Deposit Account No. above.

Applicant respectfully requests that the listed documents be made of record in the present

case.

Respectfully submitted,

Patricia A. Kammerer

Reg. No. 29,775

Attorney for Assignee

Innogenetics N.V.

HOWREY LLP 1111 Louisiana, 25th Floor Houston, Texas 77002 (713) 787-1400

Date:

February 23, 2007

Complete if Known

10/625,854

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO

Application Number

ORMATION DISCLOSURE **EMENT BY APPLICANT**

Filing Date July 23, 2003 **First Named Inventor** Andre DELACOURTE Art Unit 1649

(Use as many sheets as necessary)

Examiner Name Chang-Yu Wang Attorney Docket Number 11362.0039.NPUS01

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*					
	C17	7 CASAS, C., et al., "Massive CA 1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A{beta} 42 Accumulation in a Novel Alzheimer Transgenic Model," Am. J. Pathol. (2004), 165:1289-1300.			
	C18	DELACOURTE, A., et al., "The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease," <i>Neurology</i> (1999), 52:1158-1165.			
	C19	DELACOURTE, A., et al., "Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease," <i>Neurology</i> (2002), 59:398-407.			
	C20	DERAMECOURT, V., et al., "Biochemical staging of synucleinopathy and amyloid deposition in dementia with lewy bodies," <i>J Neuropathol. Exp. Neurol.</i> (2006), 65:278-288.			
	C21	SERGEANT, N., et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <i>Journal of Neurochemistry</i> (2003), 85:1581-1591.			
	C22	VANDERSTICHELE, H., et al., "Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment," <i>Clin. Chem.</i> (2005), 51:1650-1660.			
	C23	NICOLL, J.A., et al., "Abeta Species Removal After Abeta42 Immunization," J. Neuropathol. Exp. Neurol. (2006), 65:1040-1048.			
	C24	PATTON, R.L., et al., "Amyloid-{beta} Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis," Am. J. Pathol. (2006), 169:1048-1063.			
	C25	PICCINI, A., et al., "Beta amyloid is different in normal aging and in Alzheimer's disease," J. Biol. Chem. (2005), 280(40):34186-34192.			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO).

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.